Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of once-monthly langlenatide (HM11260C) versus placebo in type 2 diabetes on stable metformin
2013-004250-13Phase 2Completed
- Sponsor
- Hanmi Pharmaceutical
- Start
- Dec 2013
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of efpeglenatide in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by Hanmi Pharmaceutical. Primary endpoint: Change in HbA1c over 16 weeks from baseline. Started Dec 2013; status: completed.
02
Drugs
efpeglenatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2013-004250-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-004250-13.